Strategic and Tactical Competitive Insights
Intelligence that drives winning strategies, from development through commercialization.
Intelligence that drives winning strategies, from development through commercialization.
We help biopharma teams uncover threats, seize opportunities, and make strategic decisions with confidence. Our recommendations are grounded in primary research, real-time conference intelligence, and proprietary analytical tools.
How We Work
- Primary intelligence: Rapid KOL, market and industry stakeholder interviews, payer and patient research through QuickAnswers and custom engagements
- Conference coverage: Before, during, and after major congresses (e.g. ASCO, ESMO, ASH, AHA, JPM) with previews, real-time tracking, and strategic debriefs
- Wargames & workshops: AI-powered, human-in-the-loop, competitive simulations through LucidWargames, plus traditional facilitated workshops
- Continuous monitoring: Competitive landscape tracking via proprietary tools, such as LucidScope and LucidSearch
We provide decision support across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
Across the full product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
Build Intelligence That Compounds (Powered by NexusBrain)
Every engagement generates valuable insight: KOL perspectives, congress observations, wargame scenarios, competitive assumptions. Too often, this intelligence lives in static reports and forgotten slide decks.
LucidQuest engagements can be integrated with NexusBrain (nexusbrain.io), a platform that captures, structures, and activates employee-driven and expert-validated intelligence. Primary research findings, conference observations from your own teams, and wargame outputs become a searchable, cumulative asset, not one-off deliverables.
The result: every engagement makes your organization’s intelligence sharper, and gives your AI tools better inputs to work with.
Learn more at nexusbrain.io
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
March 2, 2026
Oncology Today—March 2, 2026
March 2, 2026
Hematology Today—March 2, 2026
March 2, 2026
AI in Healthcare and Digital Health Today—March 2, 2026
March 2, 2026
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
March 1, 2026
Lucid Diligence Brief: BioNTech DualityBio BNT324 Phase 3 mCRPC
February 28, 2026
Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration
February 27, 2026
AAAAI 2026 Preview: Key Allergy, Asthma and Immunology Highlights to Watch
February 27, 2026
ESGO 2026 Preview: Key Gynaecological Oncology Highlights to Watch
February 27, 2026
Respiratory Today—February 27, 2026
February 27, 2026
Vaccines Today—February 27, 2026
February 27, 2026
Public Health Video Recap—February 27, 2026
February 27, 2026